Scott Plevy, MD

Plevy, ScottAssociate Professor

Division of Gastroenterology and Hepatology

7341C MBRB, CB# 7032





Maharshak N, Plevy SE (2011). A Crohn's Disease Patient Who Does Not Respond to Infliximab: What Is Next? Clin Gastroenterol Hepatol.

Sheikh SZ, Hegazi RA, Kobayashi T, Onyiah JC, Russo SM, Matsuoka K, Sepulveda AR, Li F, Otterbein LE, Plevy SE (2011). An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol. 186(9):5506-13.

Kobayashi T, Matsuoka K, Sheikh SZ, Elloumi HZ, Kamada N, Hisamatsu T, Hansen JJ, Doty KR, Pope SD, Smale ST, Hibi T, Rothman PB, Kashiwada M, Plevy SE (2011). NFIL3 is a regulator of IL-12 p40 in macrophages and mucosal immunity. J Immunol. 186(8):4649-55

Sheikh SZ, Kobayashi T, Matsuoka K, Onyiah JC, Plevy SE (2011). Characterization of an interferon-stimulated response element (ISRE) in the Il23a promoter. J Biol Chem. 286(2):1174-80.

Uno JK, Rao KN, Matsuoka K, Sheikh SZ, Kobayashi T, Li F, Steinbach EC, Sepulveda AR, Vanhaesebroeck B, Sartor RB, Plevy SE (2010). Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. Gastroenterology. 139(5):1642-53, 1653.e1-6.

Sheikh SZ, Matsuoka K, Kobayashi T, Li F, Rubinas T, Plevy SE (2010). Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. J Immunol. 184(8):4069-73.

Davé SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D, Sepulveda AR, Fink MP, Lotze MT, Plevy SE (2009). Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol. 86(3):633-43.

Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE (2009). Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 136(2):441-50.e1.

Levy LC, Plevy SE (2008). Farm animals and inflammatory bowel disease: old MacDonald had poor hygiene. Gastroenterology. 134(3):886-7

Davé SH, Tilstra JS, Matsuoka K, Li F, Karrasch T, Uno JK, Sepulveda AR, Jobin C, Baldwin AS, Robbins PD, Plevy SE (2007). Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J Immunol. 179(11):7852-9.

Matsuoka K, Plevy S (2007). Salvation through death: preaching the dogma of apoptosis. Inflamm Bowel Dis. 13(11):1446-7.

Regueiro M, Siemanowski B, Kip KE, Plevy S (2007). Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 13(9):1093-9.

Bogunovic M, Davé SH, Tilstra JS, Chang DT, Harpaz N, Xiong H, Mayer LF, Plevy SE (2007). Enteroendocrine cells express functional Toll-like receptors. Am J Physiol Gastrointest Liver Physiol. 292(6):G1770-83.

Regueiro M, Curtis J, Plevy S (2006). Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 40(6):476-81.

Hegazi RA, Rao KN, Mayle A, Sepulveda AR, Otterbein LE, Plevy SE (2005). Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med. 202(12):1703-13.

Meier CB, Hegazi RA, Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Duerr RH, Gorfine SR, Bauer JJ, Sachar DB, Plevy SE (2005). Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis. 11(11):965-71.

Regueiro M, Kip KE, Cheung O, Hegazi RA, Plevy S (2005). Cigarette smoking and age at diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 11(1):42-7.

Plevy S (2005). A STAT need for human immunologic studies to understand inflammatory bowel disease. Am J Gastroenterol. 100(1):73-4.

pubmed Complete list of publications.